Company intelligence / Profile preview

Greenfire Bio

_Frisco_ / Austin_, Texas, United Statesgreenfirebio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Greenfire Bio is advancing a first-in-class small molecule dual SIK2/3 inhibitor GRN300 currently in a Phase I trial for ovarian cancer at MD Anderson Cancer Center. They have invested in Pacylex Pharmaceuticals which is developing PCLX001, a first-in-class N-myristoyltransferase inhibitor showing promising potency against hematologic malignancies and solid tumors, now in Phase II trials. The company also develops therapeutic vaccine candidates targeting multiple solid tumors at preclinical stages. Their strategy involves acquiring or licensing early-stage assets to develop through proof-of-concept clinical studies[1][4][5].

Therapeutic areas: Oncology
Modalities: Small molecule inhibitors (e.g., SIK2/3 inhibitor GRN300)Therapeutic vaccines (heteroclitic epitope activated therapy)Biological products
Industry: Biotech

Drug pipeline

2 assets

GRN-300

Phase 1

Indications: Ovarian cancer, Triple-negative breast cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Investment partnership with Pacylex Pharmaceuticals to advance the novel oncology drug PCLX001.[5]

Beyond the preview

Go deeper on Greenfire Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Greenfire Bio.

Explore the full profile